BSE filing, NSE: CORONA. Summary written from the filing by ALFA Finder's alert engine.
Corona Remedies Ltd: key numbers
- Share price
- ₹2,200.60
- Market cap
- ₹13,459 Cr
- Revenue (annual)
- ₹1,403 Cr
- Net profit (annual)
- ₹185.1 Cr
- P/E (TTM)
- 67.6×Sector 46.1×
- Promoter holding
- 69.00%+0.00% QoQ
- FII holding
- 4.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Corona Remedies Ltd
All →Corona Remedies Business Update
Corona Remedies received GMP Compliance Certification from Brazil's ANVISA for its OSD and Hormone facilities in Ahmedabad. This validates export eligibility to the Brazilian pharmaceutical market.
Corona Remedies Board Meeting Date
Corona Remedies Limited will hold a board meeting on October 30, 2026. The board will consider unaudited financial results for the quarter and half-year ended September 30, 2026.
Corona Remedies Other Announcement
This filing contains quarterly shareholding pattern disclosures for Corona Remedies Ltd. It provides details on share distribution as required by regulatory compliance norms.
Corona Remedies Capital Structure Change
Sepia Investments Limited, Sage Investment Trust, and Anchor Partners sold 2,629,880 equity shares of Corona Remedies Limited. This non-promoter stake sale is disclosed under SEBI SAST regulations.
Corona Remedies Price Movement Clarification
CORONA Remedies Limited clarified that the recent increase in its share trading volume is purely market-driven and no undisclosed price-sensitive information exists.
Corona Remedies Earnings Call Transcript: Key Takeaways
Corona Remedies reported robust Q1 FY27 results with 21.9% revenue growth and 33.5% EBITDA growth. Strategy focuses on chronic therapies and scaling brand portfolios.
- Call
- Guides 20% growth
Other credit rating announcements
All →GSPL Transmission Credit Rating
CARE Ratings assigned GSPL Transmission a CARE AA+ rating on bank facilities with a stable outlook. The rating cites nil debt and strong liquidity.
Meghmani Organics Credit Rating
India Ratings assigned Meghmani Organics' bank loan facilities of INR 11,000 million a rating of IND A/Stable/IND A1. The filing encloses the rating letter and a facilities breakup.
JSW Cement Credit Rating
CRISIL reaffirmed JSW Cement's long-term rating at AA-/Stable and its short-term ratings at A1+. No new borrowing or fund raise is announced.
Tejas Networks Credit Rating
ICRA reaffirmed Tejas Networks' [ICRA]A+(Stable) long-term rating and [ICRA]A1+ short-term rating. The rating covers Rs.6,000 Crore of credit facilities and a Rs.500 Crore CP programme.
HDB Financial Services Credit Rating
CARE Ratings reaffirmed HDB Financial Services' AAA rating with Stable outlook across its debt instruments. Its A1+ short-term rating was also reaffirmed.
Asian Energy Services Credit Rating
Asian Energy Services Limited disclosed that CRISIL maintained its 'Watch Developing' rating on INR 317.5 Crore of bank facilities. The watch continues pending final Ministry of Petroleum approval for the merger of its parent, Oilmax Energy.